NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report

NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report

IntroductionA 73-year-old Chinese woman with no smoking history was diagnosed with stage IV adenocarcinoma of the lung in August 2020, presenting with left chest pain and multiple lung lesions.Patient concernsThe patient experienced chest pain for 2 months before diagnosis. Initial CT scans revealed...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jielin Li, Yunyun Shi, Mengge Zheng, Chenkang Yang, Hong Gao, Xiaoling Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Pharmacology
Subjects:	EGFR-mutated NSCLC NTRK-fusion larotrectinib resistance case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1571777/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature
by: Marianna Peroni, MD, et al.
Published: (2025-08-01)

Mammary analogue secretory carcinoma of the salivary gland with NTRK fusions: new approaches for diagnostics and targeted therapy (review)
by: A. V. Ignatova, et al.
Published: (2020-07-01)

Sructural rearrangements of NTRK genes: characteristics, methods of detection and targeted therapy for cancer
by: A. A. Kechin, et al.
Published: (2022-01-01)

Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR‐TKI Treatment: A Retrospective Cohort Study
by: Yi‐Tse Su, et al.
Published: (2025-07-01)

Case Report: Dramatic response to entritinib in a patient with gastrointestinal stromal tumor positive for NTRK3 fusion
by: Guomin Dong, et al.
Published: (2025-08-01)

Advancing EGFR mutation subtypes prediction in NSCLC by combining 3D pretrained ConvNeXt, radiomics, and clinical features
by: Peng Hao, et al.
Published: (2024-11-01)

Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations
by: Le LT, et al.
Published: (2025-07-01)

The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment
by: Nicha Zungsontiporn, et al.
Published: (2025-08-01)

Cudratricusxanthone A exhibits antitumor activity and enhances chemosensitivity to cisplatin against NSCLC via targeting EGFR
by: Peiyuan Sun, et al.
Published: (2025-08-01)

Ethyl acetate extract of Ruta graveolens: a specific and potent inhibitor against the drug-resistant EGFR_T790M mutant in NSCLC
by: Vikas Kumar, et al.
Published: (2025-04-01)

Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance
by: Linjuan Wang, et al.
Published: (2025-07-01)

Investigating the correlation between IDO1/PD-L1 expression or co-expression and EGFR/KRAS gene mutations in advanced NSCLC
by: Zhidong Yin, et al.
Published: (2025-08-01)

Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation
by: Yan’e Liu, et al.
Published: (2025-06-01)

A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1‐3 Rearrangements
by: Shengnan Du, et al.
Published: (2025-07-01)

De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis
by: Lili Shen, et al.
Published: (2025-08-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-02-01)

Comprehensive evaluation of risk factors for LNM and distant metastasis in patients with NSCLC
by: Linghao Ni, et al.
Published: (2025-08-01)

Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes
by: Meng Zhang, et al.
Published: (2025-08-01)

MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK/ERK pathway activation by inflammatory cytokines
by: Hyun-Min Ryu, et al.
Published: (2025-08-01)

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report
by: Daphnée Demers, et al.
Published: (2025-05-01)

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)

Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary
by: Serena Brundu, et al.
Published: (2023-02-01)

Sd-021, derivatives of decursin, inhibits tumorigenesis in NSCLC by inhibiting the EGFR/STAT3 signaling pathway
by: Hyun-Ha Hwang, et al.
Published: (2025-07-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)

MONITORING OF EGFR MUTATIONS IN THE CIRCULATING TUMOR DNA FROM BLOOD PLASMA OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
by: V. A. Shamanin, et al.
Published: (2018-11-01)

Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach
by: Andrew J. Pellatt, et al.
Published: (2025-07-01)

Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC
by: Ceva Wicaksono Pitoyo, et al.
Published: (2022-07-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)

Assessment of Exhaled Breath Condensate for ALK, RET, ROS1, and NTRK1 Fusion Transcript Detection in NSCLC: Comparison With Tissue and Liquid Biopsy Samples
by: Aslı Tetik Vardarlı, et al.
Published: (2025-01-01)

Case Report: A Bilateral Synchronous Primary Non‐Small Cell Lung Cancer Patient With Two Different EGFR Mutations
by: Thanh‐Dung Quach, et al.
Published: (2025-08-01)

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
by: Ilaria Marrocco, et al.
Published: (2021-03-01)

Triple reversal phenomenon in EGFR-mutant lung adenocarcinoma with prostate metastasis following hepatocellular carcinoma: a rare Case Report with diagnostic and therapeutic implications
by: Jieyan Luo, et al.
Published: (2025-07-01)

A novel radiomics model combining GTVp, GTVnd, and clinical data for chemoradiotherapy response prediction in patients with advanced NSCLC
by: Ya Li, et al.
Published: (2025-07-01)

Functional tumor-derived exosomes in NSCLC progression and clinical implications
by: Yuxin Gao, et al.
Published: (2025-03-01)

The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice
by: E. V. Karabina, et al.
Published: (2018-11-01)

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
by: Huijuan Wang, et al.
Published: (2020-01-01)

Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China
by: Zhujun Chen, et al.
Published: (2025-07-01)

PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
by: Samaneh Moradi, et al.
Published: (2025-03-01)

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene
by: Ewelina Testoni, et al.
Published: (2016-01-01)

Management and Long-Term Monitoring of a Young Patient with Pheochromocytoma and RET Mutation: A Case Report
by: Zhang Q, et al.
Published: (2025-03-01)